Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Hematologic Cancers

Atheer Kaddis presents his own personal advice on what pharmacists should do to navigate through the healthcare system.
Hear Atheer Kaddis describe how the role of the pharmacist is changing in hematology and oncology.
Atheer Kaddis presents the role of the pharmacist with regards to polycythemia vera and describes why it is unique.
This article discusses ongoing clinical investigations of the agent in a wide range of therapeutic areas.
Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations.
Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors.
At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as aggressive non-Hodgkin lymphoma (NHL).

With 2 treatment regimens for advanced Hodgkin lymphoma equivalent in their long-term effectiveness, one regimen’s less severe side-effect profile may play a role in treatment choice, according to study results from the Gruppo Italiano di Terapie Innovative nei Linfomi and the Intergruppo Italiano Linfomi.

A combination of fludarabine, pixantrone, dexamethasone, and rituximab (FPD-R) achieved major durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) in a single-arm phase 1 dose-escalation study. The study identified a dose of 120 mg/m2pixantrone as the recommended dose for this regimen. The overall response rate with this regimen was 89%, and the regimen was well tolerated with no grade 3/4 cardiovascular adverse events. Grade 3/4 lymphopenia occurred, however, in 89% of patients and leukopenia in 79%.

 

A combination of fludarabine, pixantrone, dexamethasone, and rituximab (FPD-R) achieved major durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) in a single-arm phase 1 dose-escalation study. The study identified a dose of 120 mg/m2pixantrone as the recommended dose for this regimen. The overall response rate with this regimen was 89%, and the regimen was well tolerated with no grade 3/4 cardiovascular adverse events. Grade 3/4 lymphopenia occurred, however, in 89% of patients and leukopenia in 79%.

 

Page 4 of 5
Results 31 - 40 of 47